Beta© 2026 Adaptrex, LLC
Beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Minimally Invasive Local Delivery of Cardiac Gene Therapy - Project Summary Cardiovascular Diseases (CVD) Are the Leading Cause of Death in the United States, and Current Therapies Are Hindered by Inefficient Delivery Methods, High Systemic Off-target Exposure, and Prohibitive Costs, Particularly for Gene Therapies. Corami Biotech’s Platform Combines a Minimally Invasive Epicardial Delivery Device (epicor™) and a Tunable Hydrogel (gelcor™) Which Together Localize Therapeutic to the Heart Leading to Significantly Lower Effective Dose of Gene Therapy Compared to Systemic Delivery While Minimizing Off-target Expression.
Committed
$1.3 Million
Paid out
$353.4K
27%
Committed, not yet paid
$940.0K
73%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…